Docoh
Loading...
Sign up Log in

RMD Resmed

ResMed, Inc. engages in the development, manufacturing, distribution, and marketing of medical equipment and software solutions. The company operates through the following segments: Sleep and Respiratory Care, and SaaS. The Sleep and Respiratory Care segment engages in the sleep and respiratory disorders sector of the medical device industry. The SaaS segment engages in the supply of business management software as a service to out-of-hospital health providers. Its product portfolio includes devices, diagnostic products, mask systems, headgear and other accessories, and dental devices. The company was founded by Peter C. Farrell in June 1989 and is headquartered in San Diego, CA.

Company profile

Ticker
RMD
Exchange
NYSE
Website
www.resmed.com/
CEO
Michael Farrell
Employees
Incorporated
Delaware
Location
California
Fiscal year end
Jun 30
Sector
Manufacturing > Surgical and Medical Instrument Manufacturing
Industry (SIC)
Surgical & Medical Instruments & Apparatus
Boston Scientific • Baxter International • Becton, Dickinson And • 3M • Stryker • Teleflex • Hill-Rom • Integra Lifesciences • Nuvasive • Haemonetics ...
SEC CIK
0000943819
Corporate docs
IRS number
980152841

RMD stock data

(
)

News

Pro users get this 30m faster
Benzinga's Top Ratings Upgrades, Downgrades For March 16, 2021
16 Mar 21
Needham Upgrades ResMed to Buy, Announces $229 Price Target
16 Mar 21
Needham analyst Mike Matson upgrades ResMed (NYSE:RMD) from Hold to Buy and announces $229 price target.
Recap: ResMed Q2 Earnings
28 Jan 21
Shares of ResMed (NYSE:RMD) were flat in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 16.53% year over year to $1.41, which beat the estimate of $1.26.
ResMed Q2 EPS $1.41 Beats $1.26 Estimate, Sales $800.00M Beat $783.18M Estimate
28 Jan 21
The Daily Biotech Pulse: Decision Day For Amgen, Zymeworks Sinks On Data, Ortho Clinical Diagnostics IPO
28 Jan 21

Press releases

Pro users get this 30m faster
Nyxoah Reports Full Year 2020 Results
9 Apr 21
Nyxoah Reports Full Year 2020 Results Conference call and webcast today at 3pm CET / 9am ET Mont-Saint-Guibert, Belgium – 9 April 2021 – Nyxoah SA (Euronext Brussels: NYXH) ("Nyxoah" or the "Company"),
Nyxoah Reports Full Year 2020 Results
9 Apr 21
Nyxoah Reports Full Year 2020 Results Conference call and webcast today at 3pm CET / 9am ET Mont-Saint-Guibert, Belgium – 9 April 2021 – Nyxoah SA (Euronext Brussels: NYXH) ("Nyxoah" or the "Company"),
ResMed to Report Third Quarter Fiscal 2021 Earnings on April 29, 2021
8 Apr 21
SAN DIEGO, April 08, 2021 (GLOBE NEWSWIRE) -- ResMed (NYSE:RMD, ASX: RMD)) today announced it plans to release financial and operational results for the third quarter of fiscal year 2021 on Thursday, April 29, 2021,
New Survey Shows Stress Over the Past Year Is Negatively Impacting the Quality of Sleep for Half of Americans
15 Mar 21
Tactile Medical Appoints Kristie Burns as Senior Vice President of Marketing & Clinical Affairs
15 Mar 21

Calendar

29 Mar 21
18 Apr 21
30 Jun 21

Financial summary

Financial statements Chart RMD financial data
Quarter (USD)
 Dec 20 Sep 20 Jun 20 Mar 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
 Jun 20 Jun 19 Jun 18 Jun 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Resmed earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 255.87M 255.87M 255.87M 255.87M 255.87M 255.87M
Cash burn (monthly) 55.18M (positive/no burn) (positive/no burn) (positive/no burn) (positive/no burn) (positive/no burn)
Cash used (since last report) 199.65M n/a n/a n/a n/a n/a
Cash remaining 56.21M n/a n/a n/a n/a n/a
Runway (months of cash) 1.0 n/a n/a n/a n/a n/a

Beta Read what these cash burn values mean

Recent insider trades

RMD insider ownership history Insider history
Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
15 Apr 21 Douglas Robert Andrew ResMed Common Stock Sell Dispose S Yes Yes 207.45 964 199.98K 210,407
12 Apr 21 Sandercock Brett ResMed Common Stock Sell Dispose S No Yes 198.47 2,500 496.18K 94,922
12 Apr 21 James Hollingshead ResMed Common Stock Sell Dispose S No Yes 200 4,800 960K 83,046
5 Apr 21 David Pendarvis ResMed Common Stock Sell Dispose S No Yes 196.15 1,487 291.68K 129,294
1 Apr 21 Rajwant Sodhi ResMed Common Stock Sell Dispose S No Yes 194.14 1,500 291.21K 30,088
Data from 3, 4 and 5 filings. Stock values as filed, not updated for current price.

Institutional ownership Q4 2020

RMD institutional ownership history Ownership history

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

6.1% owned by funds/institutions
13F holders
 Current Prev Q Change
Total holders 1 0 NEW
Opened positions 1 0 NEW
Closed positions 0 0
Increased positions 0 0
Reduced positions 0 0
13F shares
 Current Prev Q Change
Total value 1.88B 0 NEW
Total shares 8.82M 0 NEW
Total puts 0 0
Total calls 0 0
Total put/call ratio – – –
Largest owners
 Shares Value Change
WCM Investment Management 8.82M $1.88B NEW
Largest transactions
 Shares Bought/sold Change
WCM Investment Management 8.82M +8.82M NEW
Data from 13F filings. Stock values as filed, not updated for current price. Long positions only.

Financial report summary

?
Competition
Lianluo Smart • Itamar Medical
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. junior Avg
New words: cancellation, closure, Concentrator, half, minimal, POC, sufficient
Removed: October, procurement
From filing 10-Q 2021 Q2

Financial reports

View all
10-K/A
2020 FY
Annual report (amended)
29 Mar 21
10-Q
2021 Q2
Quarterly report
28 Jan 21
10-Q
2021 Q1
Quarterly report
29 Oct 20
10-K
2020 FY
Annual report
12 Aug 20
10-Q
2020 Q3
Quarterly report
30 Apr 20
10-Q
2020 Q2
Quarterly report
30 Jan 20
10-Q
2020 Q1
Quarterly report
24 Oct 19
10-K
2019 FY
Annual report
7 Aug 19
10-Q
2019 Q3
Quarterly report
2 May 19
10-Q
2019 Q2
Quarterly report
31 Jan 19

Current reports

View all
8-K
ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2021
28 Jan 21
8-K
Submission of Matters to a Vote of Security Holders
20 Nov 20
8-K/A
Other Events
5 Nov 20
8-K
ResMed Inc. Announces Results for the First Quarter of Fiscal Year 2021
29 Oct 20
8-K
ResMed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2020
5 Aug 20
8-K
ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2020
30 Apr 20
8-K
Amendments to Articles of Incorporation or Bylaws
26 Feb 20
8-K
ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2020
30 Jan 20
8-K
Submission of Matters to a Vote of Security Holders
22 Nov 19
8-K
ResMed Inc. Announces Results for the First Quarter of Fiscal Year 2020
24 Oct 19

Registration and prospectus

View all
S-8
Registration of securities for employees
13 Aug 20
S-8
Registration of securities for employees
30 Apr 18
S-8
Registration of securities for employees
27 Feb 14
S-8
Registration of securities for employees
31 Jan 13
S-8
Registration of securities for employees
9 May 12
S-8
Registration of securities for employees
27 May 10
S-8
Registration of securities for employees
25 Jan 10
S-8
Registration of securities for employees
10 Dec 08
S-8
Registration of securities for employees
30 Jan 07
S-8
Registration of securities for employees
30 Jan 07

Proxies

View all
DEFA14A
Additional proxy soliciting materials
6 Oct 20
DEF 14A
Definitive proxy
6 Oct 20
DEFA14A
Additional proxy soliciting materials
8 Oct 19
DEF 14A
Definitive proxy
8 Oct 19
DEFR14A
Revised proxy
30 Oct 18
DEFA14A
Additional proxy soliciting materials
3 Oct 18
DEF 14A
Definitive proxy
3 Oct 18
DEFA14A
Additional proxy soliciting materials
25 Sep 17
DEF 14A
Definitive proxy
24 Sep 17
DEF 14A
Definitive proxy
25 Sep 16

Other

View all
SD
Conflict minerals disclosure
22 May 20
SD
Conflict minerals disclosure
22 May 19
SD
Conflict minerals disclosure
29 May 18
SD
Conflict minerals disclosure
23 May 17
UPLOAD
Letter from SEC
16 Jan 17
UPLOAD
Letter from SEC
4 Jan 17
CORRESP
Correspondence with SEC
19 Dec 16
UPLOAD
Letter from SEC
28 Nov 16
SD
Conflict minerals disclosure
30 May 16
UPLOAD
Letter from SEC
14 Dec 15

Ownership

View all
4
RESMED / Robert Andrew Douglas ownership change
16 Apr 21
4
RESMED / James Hollingshead ownership change
13 Apr 21
4
RESMED / Brett Sandercock ownership change
13 Apr 21
4
RESMED / DAVID PENDARVIS ownership change
6 Apr 21
4
RESMED / Rajwant Sodhi ownership change
5 Apr 21
4
RESMED / Robert Andrew Douglas ownership change
16 Mar 21
4
RESMED / Brett Sandercock ownership change
11 Mar 21
4
RESMED / DAVID PENDARVIS ownership change
4 Mar 21
4
RESMED / Rajwant Sodhi ownership change
2 Mar 21
4
RESMED / RONALD R TAYLOR ownership change
22 Feb 21

Patents

View all
APP
Utility
Ventilator Apparatus and Method
8 Apr 21
A respiratory treatment apparatus configured to provide a flow of breathable gas to a patient, including a breathable air outlet, an outside air inlet, and an pneumatic block module, wherein the pneumatic block module includes: a volute assembly including an inlet air passage, a mount for a blower and an outlet air passage; the blower being mounted in the mount such that an impeller of the blower is in a flow passage connecting the inlet air passage and the outlet air passage; a casing enclosing the volute assembly, wherein air passages within the casing connect air ports on the volute assembly, wherein the inlet air passage of the volute assembly is in fluid communication with the outside air inlet and the outlet air passage of the volute assembly is in fluid communication with the air outlet.
GRANT
Utility
Blower
9 Mar 21
A blower includes a housing including an inlet and an outlet, a stationary component provided to the housing, an impeller positioned between the inlet of the housing and the stationary component, a shield portion including an outer edge substantially aligning with or extending beyond an outer edge of the impeller, and a motor adapted to drive the impeller.
GRANT
Utility
Ventilator apparatus and method
26 Jan 21
A respiratory treatment apparatus configured to provide a flow of breathable gas to a patient, including a breathable air outlet, an outside air inlet, and an pneumatic block module, wherein the pneumatic block module includes: a volute assembly including an inlet air passage, a mount for a blower and an outlet air passage; the blower being mounted in the mount such that an impeller of the blower is in a flow passage connecting the inlet air passage and the outlet air passage; a casing enclosing the volute assembly, wherein air passages within the casing connect air ports on the volute assembly, wherein the inlet air passage of the volute assembly is in fluid communication with the outside air inlet and the outlet air passage of the volute assembly is in fluid communication with the air outlet.
GRANT
Utility
Electronic management of sleep related data
19 Jan 21
A system and method electronically manages sleep related data obtained by a diagnostic device.
GRANT
Utility
Compression apparatus and systems for circulatory disorders
19 Jan 21
A garment for providing circulatory system disorder therapy includes a skin contacting layer, a backing layer, and a coupling.

Transcripts

View all
2020 Q1
Earnings call transcript
29 Oct 20
2020 Q4
Earnings call transcript
5 Aug 20
2020 Q3
Earnings call transcript
30 Apr 20
2020 Q2
Earnings call transcript
30 Jan 20
2020 Q1
Earnings call transcript
24 Oct 19
2019 Q4
Earnings call transcript
25 Jul 19
2019 Q3
Earnings call transcript
3 May 19
2019 Q2
Earnings call transcript
24 Jan 19
2019 Q1
Earnings call transcript
25 Oct 18
2018 Q4
Earnings call transcript
2 Aug 18

Reddit threads

View all